Sort
40,608 grants matching “prostate cancer”
Investigating Correlates and Therapeutics of Fatigue in Cancer Patients
$1,274,401Leorey Saligan · National Institute Of Nursing Research · ZIA · FY2021 · NR
Plant-based diets and risk of cancer
$1,274,338Gary E. Fraser · Loma Linda University · U01 · FY2015 · CA
2/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama Ca Ctr Partnership
$1,274,218Roberta M Troy · Tuskegee University · U54 · FY2016 · CA
INVARIANT NKT CELL LIGANDS FOR PROSTATE CANCER VACCINES
$1,273,727Beth Israel Deaconess Medical Center, Inc. · · FY2009 · Department of the Army
Novel Molecular Therapies of Prostate Cancer
$1,273,229Dario C. Altieri · Wistar Institute · P01 · FY2010 · CA
Novel Molecular Therapies of Prostate Cancer
$1,272,322Dario C. Altieri · Wistar Institute · P01 · FY2016 · CA
PROPRIETARY ARGININE VASOPRESSIN RECEPTOR TYPE 1A (AVPR1A) ANTAGONISTS FOR TREATMENT OF LETHAL PROSTATE CANCER
$1,272,102University Of Miami · · FY2025 · Defense Health Agency
Decoding mechanisms underlying metabolic dysregulation in obesity and digestive cancer risk
$1,271,961Deirdre Kay Tobias · Brigham And Women'S Hospital · U01 · FY2023 · CA
Breast & Prostate Cancer & Hormone-Related Gene Variants
$1,271,770David John Hunter · Brigham And Women'S Hospital · U01 · FY2006 · CA
Somatic Mutations and Their Etiological Determinants for Breast Cancer in African American Women
$1,271,461Song Yao · Roswell Park Cancer Institute Corp · R01 · FY2022 · CA
Prevention of Alzheimer's Diseae by Vitamin E and Selenium
$1,270,945Frederick Schmitt · University Of Kentucky · R01 · FY2012 · AG
Photodynamic Therapy - Basic Science Studies
$1,270,830Healthone Alliance · P01 · FY2005 · CA
Modeling Precision Interventions for Prostate Cancer Control
$1,270,463Ruth D Etzioni · Fred Hutchinson Cancer Center · U01 · FY2022 · CA
INTERROGATING THE SAFETY AND EFFICACY OF A NOVEL STEAP1 CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PROSTATE CANCER.
$1,270,330University Of California, Los Angeles · · FY2021 · Defense Health Agency
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities ( 2 of 3)
$1,269,768Harold L Moses · Vanderbilt University · U54 · FY2014 · CA
CLONAL HEMATOPOIESIS AS A DETERMINANT FOR BONE MARROW TOXICITIES FOR TARGETED RADIATION THERAPIES IN PROSTATE CANCER
$1,269,699Weill Medical College Of Cornell University · · FY2022 · Defense Health Agency
TUMOR SUPPRESSORS INVOLVED IN MULTIPLE TUMOR TYPES
$1,269,503Columbia University Health Sciences · P01 · FY2000 · CA
INBRE RESEARCH CORE
$1,268,939Roberta Fishman Colman · University Of Delaware · P20 · FY2007 · RR
TRANSMEMBRANE PROSTATIC ACID PHOSPHATASE IS A MARKER, DRIVER AND THERAPEUTIC TARGET FOR LETHAL PROSTATE CANCER.
$1,267,922Icahn School Of Medicine At Mount Sinai · · FY2021 · Defense Health Agency
CENTRAL DATA COLLECTION CENTER (CDCC) CONTINUED FOLLOW-UP OF PLCO
$1,267,394Barbara B O'Brien · Westat, Inc. · N02 · FY2011 · CA
South Carolina Cancer Disparities Research Center (SC CADRE)
$1,265,640Marvella Elizabeth Ford · Medical University Of South Carolina · U54 · FY2018 · CA
South Carolina Cancer Disparities Research Center (SC CADRE)
$1,265,194Marvella Elizabeth Ford · Medical University Of South Carolina · U54 · FY2017 · CA
CHARACTERIZATION OF EARLY STAGE PROSTATE CANCER
$1,264,810Sidney Kimmel Cancer Center · U01 · FY2003 · CA
PLCO Trial Etiologic and Early Marker Study
$1,264,772Neal Freedman · Division Of Cancer Epidemiology And Genetics · ZIA · FY2022 · CA
APT: the Analytical Proteomics Team
$1,264,608Fred E Regnier · Purdue University · U24 · FY2006 · CA